Know Cancer

or
forgot password

Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life


N/A
18 Years
N/A
Open (Enrolling)
Both
Squamous Cell Carcinoma of the Oropharynx

Thank you

Trial Information

Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life


Inclusion Criteria:



- 18 years of age or older

- Diagnosis of squamous cell carcinoma of the oropharynx confirmed by the pathology
department at MSKCC

- Completed last treatment for oropharynx cancer (surgery, chemotherapy, or radiation)
at least 12 months and no more than 5 years before the date of study enrollment

- Known tumor status or tumor available for HPV testing [based on chromogenic in situ
hybridization with wide spectrum HPV probe (HPV III family 16 probe (Ventana) with
affinity to HPV genotypes 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, and 66) or p16
immunohistochemistry done in a Clinical Laboratory Improvement Amendment
(CLIA)-approved laboratory; if either of these 2 tests are positive, the patient is
classified as positive].

- Able to speak and read English (study questionnaire-Aim 1 and interview guide-Aim 2
are currently only available in English).

- Received at least one component of treatment for oropharynx cancer at MSKCC or the
regional network sites

- If radiation therapy was part of treatment, it must have been delivered at MSKCC or
the regional network sites

- For Aim 2 only, diagnosed with an HPV+ oropharynx cancer and have knowledge of this
diagnosis prior to study enrollment

Exclusion Criteria:

- Diagnosed with recurrent disease following completion of primary curative treatment

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

To assess quality of life in survivors

Outcome Description:

of oropharynx cancer at least one year after completion of curative treatment in patients with HPV+ disease versus HPV- disease.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Shrujal Baxi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

10-111

NCT ID:

NCT01181648

Start Date:

August 2010

Completion Date:

August 2014

Related Keywords:

  • Squamous Cell Carcinoma of the Oropharynx
  • Survivor
  • Human Papillomavirus (HPV)
  • Quality of Life
  • Surviving Oropharynx Cancer
  • 10-111
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Oropharyngeal Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Memoral Sloan Kettering Cancer CenterBasking Ridge, New Jersey  
Memorial Sloan-Kettering Cancer Center @ SuffolkCommack, New York  11725
Memoral Sloan Kettering Cancer Center at PhelpsSleepy Hollow, New York  10591
Memorial Sloan-Kettering at Mercy Medical CenterRockville Centre, New York